New drug aims to stop the agonizing itch of dialysis
NCT ID NCT04711603
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 3 trial tested a drug called MR13A9 in 178 adults on hemodialysis who suffer from severe itching (uremic pruritus). The study compared MR13A9 to a placebo to see if it reduces itch intensity, measured by a daily 0-10 rating scale. If successful, MR13A9 could become a new treatment option for this distressing symptom.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MR13A9 (a drug given intravenously)
- What this could lead to
- If it works, this could provide a new option to reduce severe itching in people on hemodialysis.
- What could go wrong
- This is a single Phase 3 trial with 178 participants. The drug may not work better than placebo, and long-term safety is still being checked.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UREMIC PRURITUS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Multiple Locations, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.